| Biomarker ID | 255 |
| PMID | 18428198 |
| Year | 2008 |
| Biomarker | C-reactive protein (CRP) |
| Biomarker Basis | Concentration Based (ng/ml) |
| Biomolecule | Protein |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Increased in Overall Survival |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 0.741 (95% CI: 0.596-0.920) |
| Effect on Pathways | Pathways Include:-Vitamin B12 metabolism,Selenium pathway, Folate metabolism,Interleukin-6 signaling pathway,Complement cascade |
| Experiment | PSA Decline Vs No PSA decline |
| Type of Biomarker | Prognostic |
| Cohort | 250 patients were considered for this placebo control study, out of which 160 blood plasma samples were used for analysis. (64%) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.0068 |
| Method Used | sandwich immunoassay |
| Clinical | Yes |
| Remarks | Using Cox Regression Analysis. PSA decline was defined as a ≥50% reduction that was confirmed ≥28 days later. |
| Clinical Trial Number | NCT00043576 |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CRP |